DYRK2 Antikörper (N-Term)

Produktnummer ABIN391770

Dieses Anti-DYRK2-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von DYRK2 in WB und IHC (p). Geeignet für Human. Dieses Primary Antibody wurde in 8+ Publikationen zitiert.

Kurzübersicht für DYRK2 Antikörper (N-Term) (ABIN391770)

Target: DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser DYRK2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: RB3008

Produktdetails anti-DYRK2 Antikörper

Bindungsspezifität: AA 105-135, N-Term

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This DYRK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 105-135 amino acids from the N-terminal region of human DYRK2.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Haltbarkeit: 6 months

Referenzen für anti-DYRK2 Antikörper (ABIN391770)

Mimoto, Imawari, Hirooka, Takeyama, Yoshida: "Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer." in: Oncogene, Vol. 36, Issue 13, pp. 1862-1872, (2017) (PubMed).

Nomura, Suzuki, Takahashi, Terasaki, Kimata, Terasaki, Hamasaki, Kimura, Shimizu, Kondo: "Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy." in: BMC urology, Vol. 15, pp. 53, (2015) (PubMed).

Moreno, Lara-Chica, Soler-Torronteras, Caro, Medina, Álvarez, Salvatierra, Muñoz, Calzado: "The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer." in: PLoS ONE, Vol. 10, Issue 11, pp. e0143376, (2015) (PubMed).

Enomoto, Yamashita, Yoshinaga, Fukami, Miyahara, Nabeshima, Iwasaki: "Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer." in: Tumour biology, Vol. 35, Issue 11, pp. 11021-5, (2014) (PubMed).

Taira, Mimoto, Kurata, Yamaguchi, Kitagawa, Miki, Yoshida: "DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells." in: The Journal of clinical investigation, Vol. 122, Issue 3, pp. 859-72, (2012) (PubMed).

Pérez, García-Limones, Zapico, Marina, Schmitz, Muñoz, Calzado: "Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways." in: Journal of molecular cell biology, Vol. 4, Issue 5, pp. 316-30, (2012) (PubMed).

Yamashita, Chujo, Tokuishi, Anami, Miyawaki, Yamamoto, Kawahara: "Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma." in: The Journal of thoracic and cardiovascular surgery, Vol. 138, Issue 6, pp. 1303-8, (2009) (PubMed).

Yamashita, Chujo, Moroga, Anami, Tokuishi, Miyawaki, Kawano, Takeno, Yamamoto, Kawahara: "DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer." in: Anticancer research, Vol. 29, Issue 7, pp. 2753-7, (2009) (PubMed).

Details zu DYRK2

Target: DYRK2 (Dual-Specificity tyrosine-(Y)-phosphorylation Regulated Kinase 2 (DYRK2))

Andere Bezeichnung: DYRK2

Hintergrund: DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro.

Molekulargewicht: 66652

Gen-ID: 8445

NCBI Accession: NP_003574, NP_006473

UniProt: Q92630

Pathways: Regulation of Carbohydrate Metabolic Process